Manuel Vergara, MD
Epilepsy · Lawrenceville, NJNPI 1487638268
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,281 of the $2,547 with a category attached, or 89.6%. 20 manufacturers reported payments, led by AbbVie at 46.1% of the total. 2025 is the largest year on record at $950, more than ten times the $59 reported in 2019.
Across 180 payments — averaging $14.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$242
- Argenx US, Inc.$165
- Teva Pharmaceuticals USA, Inc.$143
- Axsome Therapeutics, Inc.$137
- Novartis$123
- plus $560 from 14 others
What the payments were for
- Food & beverage$2,28190%
- Education$26610%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 126 | $1,175 |
| Johnson & Johnson | 6 | $242 |
| Argenx US, Inc. | 7 | $165 |
| Teva Pharmaceuticals USA, Inc. | 3 | $143 |
| Axsome Therapeutics, Inc. | 2 | $137 |
| Novartis | 8 | $123 |
| Neurocrine Biosciences, Inc. | 5 | $106 |
| Pfizer | 4 | $69 |
| Boston Scientific | 2 | $57 |
| Eisai Inc. | 3 | $57 |
| Grifols USA, LLC | 2 | $43 |
| Biogen | 2 | $41 |
| AstraZeneca(2 entities) | 2 | $39 |
| UCB, Inc. | 2 | $38 |
| Globus Medical | 1 | $35 |
| SK Life Science, Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Sanofi | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
How this compares
Too few epilepsy providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 30 | $484,149 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 24 | $427,604 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 13 | $209,294 |
| Nurtec OdtRimegepant Sulfate | 91 | $142,229 |
| MestinonPyridostigmine Bromide | 15 | $100,154 |
| Emgality PenGalcanezumab-Gnlm | 70 | $89,425 |
| BotoxOnabotulinumtoxina | 26 | $37,016 |
| RytaryCarbidopa/Levodopa | 18 | $27,930 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $19,946 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $17,926 |
| Rasagiline Mesylate | 77 | $17,698 |
| UbrelvyUbrogepant | 15 | $15,656 |
| QuliptaAtogepant | 11 | $11,196 |
| Memantine Hcl | 253 | $8,826 |
| Carbamazepine ErCarbamazepine | 51 | $8,740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $69 | $142,22991 claims |
| AbbVieBotox, Ubrelvy, Qulipta | $1,175 | $63,86852 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few epilepsy providers in New Jerseyon file to place this against a meaningful peer group, so we don't.
Other epilepsy in Lawrenceville
- Aissa AlexeevaLawrenceville$3K
- Nicole HartmannLawrenceville$3K
- Kimberly PalangioLawrenceville$2K
- Breynn EntwistleMarlboro$4K
- Olga AlexeevaMorristown$2K
- Alma YumSummit$2K
- Palak PatelEdison$1K
- Stephen WongSummit$871
- Stefan GillenPompton Plains$871
- Helen HanNew Brunswick$52
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.